Zealand Pharma A/S (OTCMKTS:ZLDPF) Receives Consensus Recommendation of “Strong Buy” from Analysts

Shares of Zealand Pharma A/S (OTCMKTS:ZLDPF) have earned a consensus rating of “Strong Buy” from the six brokerages that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a buy recommendation and five have assigned a strong buy recommendation to the company.

Several research firms have issued reports on ZLDPF. Wells Fargo & Company upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a report on Thursday, July 24th. Barclays upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Monday, July 7th. Finally, BNP Paribas upgraded shares of Zealand Pharma A/S to a “strong-buy” rating in a research note on Tuesday, July 1st.

Zealand Pharma A/S Stock Down 10.6%

Zealand Pharma A/S stock opened at $54.60 on Friday. The company has a debt-to-equity ratio of 0.03, a quick ratio of 25.07 and a current ratio of 25.10. Zealand Pharma A/S has a 52-week low of $54.11 and a 52-week high of $141.74. The firm has a 50 day moving average price of $61.81 and a two-hundred day moving average price of $75.14. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of -21.93 and a beta of 0.68.

Zealand Pharma A/S (OTCMKTS:ZLDPF) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.77) by $0.10. Zealand Pharma A/S had a negative net margin of 2,127.09% and a negative return on equity of 13.40%. The firm had revenue of $1.14 million during the quarter, compared to analyst estimates of $248.61 million. Equities analysts predict that Zealand Pharma A/S will post -2.19 EPS for the current year.

About Zealand Pharma A/S

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.